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Products of the major histocompatibility complex (MHC) 1 play an important role 
in the recognition of antigen by cytolytic T  lymphocytes (CTL). Viral (1) and minor 
histocompatibility antigens  (2)  or chemical modifiers (3)  are recognized by CTL in 
association with H-2 antigens.  The H-2 environment  in which T  cells mature, and 
not their genotype, determines the H-2 restriction of CTL (4, 5). This was shown by 
radiation  bone  marrow chimeras,  where  an  A  stem cell  matures  in  an  (A  ×  B)F1 
environment and,  thus,  recognizes antigen  in association with  H-2  A or H-2  B.  (A  × 
B)Fa stem cells maturing in a parental environment (A) will only recognize antigen in 
association with H-2  A. 
Initially, most data suggested (5-7) that it was the H-2 environment of the thymus 
that  determined  the  specificity  of  the  CTL  repertoire.  Recently,  several  sets  of 
experiments suggest  that  the  extrathymic environment  can  also play a  role  in  the 
maturation and ultimate specificity of CTL: (a) nude mice that only possess a thymic 
rudiment  (8)  could  generate  CTL  both  in  vitro  (9-11)  and  in  vivo  (12)  when 
interleukin 2 (IL-2) was provided; (b) in nude mice grafted with a thymus, the thymus 
determined  the  H-2  restriction  when  (A  ×  B)Fa  nude  mice  were  grafted  with  a 
parental thymus, but in parental nude mice grafted with an allogeneic thymus (13) 
or an F1 thymus (14),  the parental nude environment determines the restriction;  (c) 
Kruisbeek et al.  (15)  have shown that the extrathymic environment seems to play a 
role in the 1-I-2 restriction of splenic CTL but not thymic CTL in thymus-engrafted 
nude mice. 
There is some concern that the nude mouse is a poor model for studying extrathymic 
T cell differentiation because it may have other genetic defects that may influence the 
ultimate  CTL  repertoire.  This  concern  stimulated  us  to  develop  a  better  defined 
model system for studying extrathymic T  cell differentiation. If nude mice represent 
a  model where stem cells have been able to differentiate without a  thymic influence, 
we would expect  that CTL should  be generated  in thymectomized, irradiated,  and 
bone marrow-reconstituted chimeras. Previous experiments (16)  have not shown the 
generation of CTL in such animals unless they were reconstituted with bone marrow- 
containing mature T  cells. We hypothesized that  in such animals, as in nude mice, 
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the addition of exogenous IL-2 might allow the generation of CTL. 
In  this  paper,  we  show  that  the  spleen  cells  from  thymectomized,  irradiated 
chimeras transplanted  with bone marrow depleted of Thy-1 + cells generate in vitro 
H-2-restricted  syngeneic  and  allogeneic  CTL  when  IL-2  is  added  to  the  cultures. 
These Thy-I  + cells bear a more immature phenotype than the spleen cells ofeuthymic 
mice. These results suggest that Thy-1- cells can differentiate to Thy-1 + pre-CTL by 
an extrathymic differentiation pathway. 
Materials and Methods 
Mice.  C57BL/6(B6 Thy-l.2), (B6 ×  DBA/2)F~, (B6 ×  C3H)FI, and BALB/c mice come 
from  Charles  River  Breeding  Laboratories  Inc.,  Wilmington, MA,  or  from  The Jackson 
Laboratory, Bar Harbor, ME. 6-10-wk-old animals were used in the experiments. B6 PL Thy 
a/cy (B6 Thy-1.1) were bred in the Redstone Building of the Sidney Farber Cancer Institute, 
Boston, MA. 
Thymectomy.  Adult  thymectomy was  performed  on  6-wk-old  animals anesthesized  with 
ether. The thymus was removed by vacuum aspiration. Histological evaluation of thymecto- 
mized animals did not reveal any residual thymus. 
Irradiation and Reconstitution.  B6  Thy-l.2 mice thymectomized  1 wk  before  transplant or 
nonthymectomized B6 mice were irradiated with a Cs Source (Gamma Cell 40, Atomic Energy 
of Canada, Ottawa, Canada) at 940 rad and reconstituted intravenously the same day with 2 
X 107 B6 PL Thy-t a/Cy (Thy-1.1) bone marrow cells treated with anti-Thy-1.1 antibody and 
complement (C)  (see below).  Similarly, Thy-1.1 or Thy-1.2 mice were reconstituted with anti- 
Thy-l.2 antibody plus  C-treated  bone marrow  from  Thy-l.2 mice.  Transplanted animals 
received  tetracycline hydrochloride (8%  solution) in their drinking water.  Control animals, 
irradiated and nontransplanted, died in 10-13 d. 
In Vitro  Induction ofCytolytic TLymphocytes.  Cultures were performed in 16-mm Linbro culture 
plates (Flow Laboratories, Inc., Rockville, MD)  in 2 ml of RPMI  1640 (M.  A.  Bioproduets, 
Walkersville,  MD)  supplemented with  10%  fetal  calf serum,  2  mM  L-glutamine (Gibco 
Laboratories, Grand Island Biological Co., Grand Island, NY), 5 ×  10  -5 M 2-mercaptoethanol, 
penicillin (100/~g/ml), and streptomycin (100/~g/ml). 8-18 wk after transplantation, spleen 
cells from chimeras were  used to generate primary in vitro CTL. 5 ×  106 effector  cells were 
incubated with  5  ×  106  stimulator cells  treated  with  Tris-HC1  ammonium chloride  and 
irradiated  (1,200  rad).  Trinitrophenyl (TNP)  stimulator cells  were  modified with  10  mM 
trinitrobenzenesulfonic  acid as described previously (17). Cultures were incubated for 5 d at 
37°C in a 5% CO2 incubator. 
Interleukin 2 (IL-2).  The term IL-2 refers to a partially purified supernatant obtained from 
Lewis rat spleen cells cultured for 24 h  with concanavalin A  (5 #g/ml). The fraction of the 
supernatant precipitated between 50%  and  75%  saturation of ammonium sulfate  (18) was 
dialyzed against Tris-buffered saline, resuspended in RPMI  1640, and used in cultures at a 
final concentration of 5%. 
Treatment of Cells With Monoclonal Antibody and C.  50 ×  10  n spleen cells or bone marrow cells 
were incubated for 30 min with  1 ml of a monoclonal anti-Thy-l.1 or anti-Thy-l.2 antibody 
(New England Nuclear, Boston, MA) at a dilution of 10  -3 in LI5 medium (M. A. Bioproducts) 
at room temperature. The cells were then pelleted, the supernatant discarded, and  1 ml of a 
10  -1 dilution of low toxic guinea pig C was added. After 40 min at 37°C, the cells were washed, 
and a second treatment was performed with antibody and C at the same concentration used for 
the first treatment but this time added together for 40 rain at 37°C. The cells were then washed 
twice in L 15. This procedure was used for the following: to eliminate Thy-1-positive cells from 
the bone marrow before transplanting  these cells to irradiated recipients, and to deplete spleen 
cells before stimulation in vitro or after 5 d  in culture. In the latter case,  5 ×  l0  s cells were 
treated with 0.5 ml of serum and 0.5 ml of C. 
Treatment of spleen cells  with monoclonal anti-Ly-l.2 antibody (New  England Nuclear) 
plus C was done twice using 25 ×  10  n cells and 0.5 ml of antibody at a dilution of 4 ×  10  -4, 
following the same procedure used for anti-Thy-1. 
Assay for Cytolytic T Cell Activity.  Target cells were P815 (H-2d), EL4(H-2b), RDM-4(H-2  k) 846  GENERATION OF CYTOLYTIC T  LYMPHOCYTES 
tumor or lipopolysaccharide (LPS)  lymphoblast cells, either unmodified or modified with  10 
mM  TNBS.  LPS  lymphoblasts were  generated  by culturing  spleen  cells  with  LPS  (Difco 
Laboratories, Detroit,  MI)  at  10 ~g/ml  for 48  h.  The 51Cr release  assay  was performed as 
described  previously (19), with some modifications.  Briefly, 5 ×  10  ° target cells were labeled 
•  51  with 100 btCl Na2  CrO4 (New England Nuclear) for 1 h at 37°C in Eagle's minimum essential 
medium  (MEM)  supplemented with  10% fetal calf serum, penicillin  and streptomycin,  1% 
nonessential  amino acids, and 2 mM L-glutamine.  Labeled cells were washed three times, and 
104 cells were mixed with varying numbers of effector cells in 0.2 ml of supplemented MEM in 
V-bottomed plates (Linbro Chemical Co., Hamden, CT) and incubated at 37°C in 5% CO2. 
100 p,l of supernatant I was harvested to determine radioactivity released.  The percentage of 
chromium released was calculated as percent specific release: 51Cr released by immune cells - 
51Cr released by normal cells/maximum 51Cr released  (with  1% deoxycholate) -  5XCr released 
by normal cells. 
Results 
Generation of Cytolytic Activity In  Vitro in Thymectomized Chimeras.  Thymectomized or 
nonthymectomized  (control)  B6  Thy-l.2  mice  were  lethally  irradiated  and  trans- 
planted  with  bone  marrow  cells  from  the  congenic  strain  B6  PL  Thy-1  a/Cy 
(Thy-1.1) depleted of Thy-1-positive cells by two treatments with anti-Thy-1.1 and C 
(Thy-l.1 ~  Thy-l.2).  Similarly, lethally  irradiated  B6 Thy-l.1  mice were reconsti- 
tuted  with  treated  Thy-l.2  bone  marrow  cells  (Thy-l.2 ~  Thy-l.1).  These  strain 
combinations were chosen to minimize possible allogeneic effects but still provide the 
ability to assess whether cells were from the recipient or donor. 8 wk after transplan- 
tation,  the  spleen cells of these chimeras were assessed  for their ability to  generate 
CTL responses in vitro. When stimulated with syngeneic B6-TNP stimulator spleen 
cells from normal mice, good cytolytic activity was obtained  against  EL4-TNP by 
spleen cells from control chimeras, but no cytolytic activity was generated by spleen 
cells from thymectomized animals (Table I). These data agree with previous reports 
(5);  however,  when  5%  IL-2  was  added  to  the  cultures,  thymectomized  animals 
generated significant cytolytic activity against  syngeneic TNP-modified cells. These 
results were obtained both for Thy-1.1 ~  Thy-l.2 chimeras and Thy-1.2 ~  Thy-1.1 
chimeras. Such results have been obtained in more than 10 experiments using different 
batches of chimeras transplanted 8-18 wk previously. Spleen cells from thymectomized 
mice co-cultured with B6 syngeneic cells did not demonstrate self reactivity, i.e., the 
ability to lyse EL4, even in the presence of IL-2 (Table II). Similarly, when stimulated 
with allogeneic (B6 ×  DBA2)Fa cells, thymectomized mice generated cytolytic activity 
only when IL-2 was added to the culture  (Table III). In all these experiments, IL-2 
alone did not have any effect (Table IV). The use of (B6 ×  DBA/2)Fa stimulator cells 
was  necessary  to  prevent  back stimulation  and  IL-2  production  by the  irradiated 
stimulator  cells.  Bone  marrow  cells  treated  with  anti-Thy-1  plus  C  and  used  to 
reconstitute  these  mice  did  not  demonstrate  any  response  to  allogeneic  or  TNP- 
modified syngeneic cells, even in the presence of IL-2 (Table V  and VI), suggesting 
that extrathymic differentiation had occurred in these chimeras to the point where 
these cells now could respond to antigen plus exogenous IL-2. 
Cytolytic T  Lymphocytes in Chimeras Are of Donor Origin.  Anti-TNP CTL generated 
from B6 Thy-l.1 --~ B6 Thy-l.2 or B6 Thy-l.2 --~ B6 Thy-l.1 chimeras were treated 
with  either  anti-Thy-l.1  antibody  and  C  or  anti-Thy-l.2  antibody  and  C.  The 
cytolytic activity was eliminated  by anti-Thy-l.1  treatment  of Thy-l.1  --~ Thy-l.2 
chimeras and  by anti-Thy-l.2  treatment  of Thy-l.2 ~  Thy-l.1  chimeras, both  for VERONIQUE  DUPREZ,  BRIAN  HAMILTON,  AND  STEVEN J.  BURAKOFF 
TAnLE  I 
Generation of Anti- TNP CTL from Spleen Cells of Thymectomized Chimeras 
847 
Experi- 
ment  Responder*  Stimulator 
Percent specific 
~lCr release of 
EL4-TNP~ 
25:1§  5:1 
Normal B6 Thy- 1.1 
Normal B6 Thy- 1.1 
Control chimera (Thy- 1.1 
Control chimera (Thy- 1.1 
Thymectomized chimera 
(Thy-l.1 ~  Thy-l.2)¶ 
Thymectomized chimera 
(Thy-l.1 ~  Thy-l.2)¶ 
Thymectomized chimera 
(Thy-l.1 ~  Thy-l.2)¶ 
Thymectomized chimera 
(Thy-l.l ~  Thy-l.2)¶ 
---, Thy-1.2)11 
--~ Thy- 1.2)11 
Normal B6 Thy- 1.2 
Normal B6 Thy-l.2 
Control chimera (Thy-l.2---* Thy-l.1)** 
Control chimera (Thy- 1.2 ~  Thy- 1.1)** 
Thymectomlzed chimera 
(Thy-l.2 ~  Thy- l. 1)~:l: 
Thymectomized chimera 
(Thy- 1.2 --* Thy- 1.1):~:~ 
B6-TNP  80  54 
B6-TNP +  IL-2  63  26 
B6-TNP  49  16 
B6-TNP +  IL-2  67  38 
B6-TNP  3  0 
B6-TNP 4- IL-2  39  16 
B6-TNP  0  0 
B6-TNP +  IL-2  32  10 
50:1  10:1 
B6-TNP  67  58 
B6-TNP +  IL-2  72  60 
B6-TNP  6O  27 
B6-TNP +  IL-2  7O  64 
B6-TNP  2  0 
B6-TNP +  IL-2  67  47 
* 5 ×  106 spleen cells were cultured 5 d with 5 ×  106 stimulator cells. IL-2 was used at a final concentration 
of 5%. IL-2 alone did not generate CTL activity. 
:[: Spontaneous release was 4-19%. 
§ Effector-to-target ratio. 
[[ Control chimera were B6 Thy-1.2 mice irradiated and reconstituted with B6 Thy-1.1 bone marrow cells 
treated with anti-Thy-1.1 +  C. 
¶ B6 Thy-l.2  mice thymectomized, irradiated, and reconstituted with B6 Thy-l.1  bone marrow cells 
treated with anti-Thy-l.1 +  C. Data from two mice. 
** Control chimera were B6 Thy-1.1 mice irradiated and reconstituted with B6 Thy-1.2 bone marrow cells 
treated with anti-Thy-l.2 +  C. 
~:1:B6 Thy-l.l  mice  thymectomized, irradiated, and reconstituted with B6 Thy-l.2  bone marrow cells 
treated with anti-Thy-l.2 +  C. 
thymectomized  animals  as  well  as  in  control  chimeras  (Table  IV).  These  results 
demonstrate  that the functional cells in thymectomized  animals are T  cells and are of 
donor  origin.  In all experiments  presented, splenic CTL  were typed  and  found  to be 
of donor origin. 
H-2 Restriction of Anti-TNP CTL in  Thymectomized Chimeras.  In  normal  mice,  anti- 
TNP  CTL  preferentially lyse autologous TNP-modified  target cells but they also lyse, 
to a  lesser degree, allogeneic TNP-coupled  cells (20). It has been proposed  (5) that the 
thymus  determines  the  H-2  restriction  of  CTL,  therefore,  we  compared  the  H-2 
restriction of anti-TNP  CTL  generated  from the spleens of chimeras  with or without 848  GENERATION  OF  CYTOLYTIC  T  LYMPHOCYTES 
TABLE  II 
Lack of CTL Reactive against Unmodified Self in Thymectomized Chimeras 
Responder*  Stimulator  Target 
Percent specific 
5tCr Release~ 
70:t  7:1§ 
Normal B6 Thy- 1.1  B6  EL4 
Normal B6 Thy- 1.1  B6 +  IL-2  EL4 
Normal B6 Thy- 1.1  B6-TNP  EL4-TNP 
20 
37 
78 
3 
10 
71 
Control chimera  u  B6  EL4 
Control chimerall  B6 +  IL-2  EL4 
Control chimerall  B6-TNP  EL4-TNP 
0 
7 
66 
0 
0 
28 
Thymectomized chimera]t  B6  EL4  0 
Thymectomized chimera  B6 +  IL-2  EL4  0 
Thymectomized chimera  B6-TNP  EL4-TNP  4 
Thymectomized chimera  B6-TNP +  IL-2  EL4-TNP  61 
0 
0 
0 
28 
* 5 ×  106 spleen cells cultured 5 d with 5 ×  106 stimulator ceils with or without 5% IL-2. 
:~ Spontaneous release for EL4 was 7% and 6-9% for EL4-TNP. 
§ Effector-to-target ratio. 
II Chimeras Thy-l.1 ~  Thy-l.2 (of legend Table I). 
TABLE  III 
Generation of AUogeneic CTL from Spleen Cells of Thymectomized Chimeras 
Responder*  Stimulator 
Percent specific 5~Cr 
Release of P8155 
20:1  4:1§ 
Control chimeral[ 
Control chimerall 
(B6 ×  DBA/2)F~  67  2 
(B6 ×  DBA/2)F1 +  IL-2  76  19 
Thymectomized chimera¶ 
Thymectomized chimera¶ 
Thymectomized chimera¶ 
Thymectomized chimera¶ 
Thymectomized chimera¶ 
Thymectomized chimera¶ 
(B6 X DBA/2)F1  0  0 
(B6 X DBA/2) +  IL-2  30  2 
(B6 X DBA/2)FI  4  0 
(B6 X DBA/2)F~ +  IL-2  62  11 
(B6 ×  DBA/2)FI  13  0 
(B6 x  DBA/2) +  IL-2  65  11 
* 5 ×  106 spleen cells were cultured for 5 d with 5 ×  106 stimulator cells with or without 5% IL-2. 
:~ Spontaneous release was from 18-21%. 
§ Effeetor-to-target ratio. 
I] Control chimera were B6 Thy-l.2 mice irradiated and reconstituted with 2 ×  10  v Thy-l,1 bone marrow 
cells treated with anti-Thy-1.1 +  C. 
¶ B6 Thy-l.2 mice thymectomized, irradiated, and reconstituted the same as control chimera. Data from 
three mice. 
a  thymus.  Table  VII  shows  that  in  thymectomized  animals,  anti-TNP  CTL  lysed 
allogeneic  TNP-modified  target  cells  (P815-TNP)  to  a  lesser extent  than  syngeneic 
TNP-modified  targets.  No  difference  in  the  H-2  restriction of anti-TNP  CTL  could 
be observed in chimeric mice with or without  a  thymus. 
Cross-Reactivity  of Alloreactive  T  Cells.  CTL  generated  from  normal  spleen  cells 
against aliogeneic cells cross-react on TNP-modified  syngeneic cells  (17).  Recently,  it 
has  been  suggested  that  the  subpopulation  of  allogeneic  CTL  that  cross-react  on VERONIQUE  DUPREZ,  BRIAN HAMILTON,  AND STEVEN J.  BURAKOFF  849 
TABLE  IV 
Treatment of CTL with Anti-Thy-1.1 or Anti-Thy-l.2 and C 
Treatment:~ 
Responder*  Stimulator  None  Anti-Thy- 
1.1+C 
Anti-Thy- 
1.2+C 
50:1  5:1[[  50:1  5:1  50:1  5:1 
Normal B6 Thy- 1.1 
Normal B6 Thy-l.2 
Control chimera§ (Thy-  1.1 ~  Thy- 1.2) 
Control chimera§ (Thy-  1.1 ~  Thy- 1.2) 
Control chimera§ (Thy-  1.1 ~  Thy- 1.2) 
Thymectomized chimera§ 
(Thy-l.1 --* Thy- 1.2) 
Thymectomized chimera§ 
(Thy-l.1 ~  Thy-l.2) 
Thymeetomized chimera§ 
(Thy-l.1 ~  Thy-l.2) 
Control chimera (Thy-l.2 ~  Thy-l.1)§ 
Thymectomized chimera 
(Thy-  1.2 ~  Thy-l.1)§ 
B6-TNP + IL-2  69  4111  1  1  78  61 
B6-TNP + IL-2  71  48  78  48  0  0 
B6-TNP  69  30  NT¶  NT 
IL-2  16  5  NT  NT 
B6-TNP + IL-2  59  25  16  6  66  33 
B6°TNP  0  0  NT  NT 
IL-2  0  0  NT  NT 
B6-TNP + IL-2  38  8  0  0  37  5 
B6-TNP + IL-2  70  59  61  44  0  2 
B6-TNP + IL-2  73  75  72  64  0  3 
* 5 ×  10  6 spleen cells were cultured for 5 d with 5 ×  10  6 stimulator cells with or without 5% IL-2. 
5 ×  10  6 cells were treated at the end of the culture twice with anti-Thy-1 + C. 
§ Chimeras were Thy- 1.1 --* Thy- 1.2 or Thy- 1.2 --~ Thy- 1.1 (Cf Legend Table I). 
11 Specific  SlCr release from EL4-TNP at the indicated effector-to-target ratios. Spontaneous release of EL4- 
TNP was 15%. 
¶ Not tested. 
TNP-modified syngeneic cells is influenced by the MHC  antigens on radioresistant 
cells in the thymus (21). If this influence on the CTL repertoire is determined by the 
thymus, no cross-reactive CTL should be found in thymectomized chimeras. Table 
VIII shows the cross-reactivity of anti-H-2  d CTL generated by spleen cells from B6 
Thy-l.1 --~ B6 Thy-l.2 and B6 Thy-l.2 ~  B6 Thy-l.1 chimeras immunized against 
(B6  ×  DBA/2)Ft  cells.  The same  degree  of cross-reactivity by alloreactive CTL  is 
observed on syngeneic modified EL4-TNP cells by spleen cells from thymectomized 
or nonthymectomized chimeras. 
It has also been observed that alloreactive CTL generated from nude mice fail to 
demonstrate cross-reactive lysis of third-party allogeneic cells  (10),  again evidence 
suggesting that the thymus may influence the ultimate CTL repertoire. Therefore, we 
investigated whether thymectomized chimeras demonstrated this cross-reactivity and 
found that,  from thymectomized or nonthymectomized chimeras, alloreactive CTL 
demonstrated lysis of third-party allogeneic targets (Table IX). 
CTL  Precursors  of  Thymectomized  Chimeras  Express  the  Phenotype  of  Immature 
CTL.  Recent  data  (22)  have shown  that  pre-CTL in normal Thy-l.1  spleens are 
difficult to lyse with anti-Thy-1.1 and C, and these cells have a low density of Thy-1.1 
antigens on  their  surface,  as  shown  by  fluorescence-activated cell  sorter  analysis. 850  GENERATION  OF  CYTOLYTIC  T  LYMPHOCYTES 
TABLE  V 
Lack of Reactivity of Bone Marrow Cells after Treatment with Anti-Thy-1.1  and C 
Responder*  Stimulator  Target 
Percent specific 
51Cr release:~ 
30:1§  3:1 
Bone marrow treated with C  BALB/c  P815  63  32 
Bone marrow treated with C  BALB/c +  IL-2  P815  62  60 
Bone marrow treated with C  B6-TNP  EL4-TNP  10  5 
Bone marrow treated with C  B6-TNP +  IL-2  EL4-TNP  37  10 
Bone marrow-treated with  BALB/c  P815  0  0 
Anti-Thy- 1.1  +  C 
Bone marrow-treated with  IL-2  P815  0  0 
Anti-Thy-l.1 +  C 
Bone marrow-treated with  BALB/c +  IL-2  P815  0  0 
Anti-Thy-l.l +  C 
Bone marrow-treated with  B6-TNP  EL4-TNP  1  4 
Anti-Thy-l.l +  C 
Bone marrow-treated with  IL-2  EL4-TNP  0  2 
Anti-Thy-l.1 +  C 
Bone marrow-treated with  B6-TNP +  IL-2  EL4-TNP  0  0 
Anti-Thy-l.1 +  C 
* Responder cells were 5  ×  108 B6 Thy-l.l bone marrow cells cultured 5 d  with 5 ×  106 stimulator cells. 
IL-2 was used at a  final concentration of 5%.  Before culture, responder ceils were treated twice with C 
alone or treated twice with anti-Thy-1.1 +  C. 
:~ Spontaneous release was 10% for P815 and 20-23% for EL4-TNP. 
§ Effector-to-target ratio. 
TABLE  VI 
Lack of Reactivity of Bone Marrow Cells after Treatment with Anti-Thy-l.2 and C 
Responder*  Stimulator  Target 
Percent specific 
51Cr release~ 
30:1§  3:1 
Bone marrow treated with C 
Bone marrow treated with C 
Bone marrow treated with C 
Bone marrow treated with C 
BALB/c  P815  62  33 
BALB/c +  IL-2  P815  63  57 
B6-TNP  EL4-TNP  16  0 
B6-TNP +  IL-2  EL4-TNP  23  7 
Bone marrow treated with  BALB/c  P815  0  0 
anti-Thy-l.2 +  C 
Bone marrow treated with  BALB/c +  IL-2  P815  0  0 
anti-Thy-l.2 +  C 
Bone marrow treated with  B6-TNP  EL4-TNP  0  0 
anti-Thy-l.2 +  C 
Bone marrow treated with  B6-TNP +  IL-2  EL4-TNP  0  0 
anti-Thy-l.2 +  C 
* Responder cells were 5 ×  106 B6 Thy-l.2 bone marrow cells cultured for 5 d with 5 ×  106 stimulator cells, 
IL-2 was used at a  final dilution of 5%.  Responder cells were treated with C  alone or treated twice with 
anti-Thy-l.2 plus C. 
:~ Spontaneous release for P815 was 10% and 20-23% for EL4-TNP. 
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TASLE VII 
H-2 Restriction of Anti-TNP CTL from Thymectomized  Chimeras 
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Responder cell*  Stimulator 
Target 
EL4-TNP  P815-TNP 
Experiment  1  20:1__.__~  4:.~1 
Control chimera§ (Thy-l.1 ~  Thy-l.2)  B6-TNP + IL-2  51  2611 
Control chimera§ (Thy-l.l ~  Thy-l.2)  B6-TNP + IL-2  73  41 
Thymectomized chimera§  B6-TNP + IL-2  46  21 
(Thy-l.1 ~  Thy-l.2) 
Thymeetomized chimera§  B6-TNP + IL-2  51  20 
(Thy-l.1 ---* Thy-l.2) 
Experiment 2  50:1  5:1 
Normal B6 Thy-l.1  B6-TNP + IL-2  69  41 
Control chimera (Thy-l.1 ~  Thy-l.2)  B6-TNP + IL-2  59  25 
Thymectomized chimera  B6-TNP + IL-2  38  8 
(Thy-l.1 ~  Thy-l.2) 
Experiment 3  10:1 
Normal B6 Thy-l.2  B6-TNP + IL-2  60 
Control chimera (Thy-l.2---* Thy-l.l)  B6-TNP + IL-2  63 
Thymeetomized chimera  B6-TNP + IL-2  47 
(Thy-l.2 ~  Thy-l.1) 
20:I  4:1 
27  2 
32  3 
23  1 
46  10 
50:1  5:1 
49  10 
29  5 
18  4 
10:1 
29 
40 
9 
* 5 ×  106 spleen cells were cultured for 5 d with 5 ×  l0  e stimulator cells and 5% IL-2. 
:~ Effector-to-target ratio. 
§ Data from two nonthymectomized and two thymectomized chimeras. 
[[ Values are percent specific 51Cr release. 
However, once stimulated to become CTL, these cells again express high amounts of 
Thy-1. A  correlation has been established between the sensitivity of cells to anti-Thy- 
1 plus C  and the density of Thy-I antigen on their cell surface: "high Thy-l" cells are 
easily lysed by antibody and C  (i.e., require less antibody), and "low Thy-l" are more 
resistant to lysis (23). High Thy-1 is characteristic of T  cells found in the thymus, and 
"low Thy-l"  of T  cells found in the spleen  (24-26).  We compared the sensitivity to 
anti-Thy-1  treatment  of splenic  pre-CTL  from  mice  with  or  without  a  thymus  to 
determine whether different amounts of Thy-1 could be found. 
Results  of Table  X  show  a  clear  difference  in  the  sensitivity of pre-CTL  from 
thymectomized  and  nonthymectomized  mice:  two  treatments  with  anti-Thy-l.1 
antibody at a  10 -a dilution plus C  eliminated anti-TNP CTL from the spleen cells of 
thymectomized animals but  did not eliminate pre-C:TL from  normal spleen cells or 
from the spleen cells of nonthymectomized chimeras. Increasing the concentration of 
antibody in nonthymectomized animals did not result in the elimination of pre-CTL 
(data not shown). Thus, the splenic pre-CTL of thymectomized mice appear to have 
a  different phenotype from that of nonthymectomized mice;  that  is, they have high 
amounts of Thy-1 antigen, whereas the spleen cells from the nonthymectomized mice 
appear to express low amounts  of Thy-1.  Fluorescence-activated cell sorter analysis 852  GENERATION  OF  CYTOLYTIC  T  LYMPHOCYTES 
TAnLE  VIII 
Cross-reactivity of AUoreactive CTL from Spleen Cells of Thymectomized Chimeras 
Experi- 
ment 
Target~ 
Responder*  Stimulator  P815  EL4-TNP 
20:1  4:1  20:1  4:1 
Control chimera§ (Thy-l.l ~  Thy-l.2)  (B6 ×  DBA/2)FI +  IL-2  76  19  36  12 
Control chimera§ (Thy-l.1 ~  Thy-l.2)  (B6 X DBA/2)FI +  IL-2  72  14  32  14 
Thymectomized chimera  (B6 X DBA/2)F1 +  IL-2  30  12  7  8 
(Thy-l.l ---* Thy-l.2)§ 
Thymectomized chimera  (B6 ×  DBA/2)FI +  IL-2  62  11  33  16 
(Thy-l.1 --} Thy-l.2)§ 
Thymectomized chimera  (B6 ×  DBA/2)Fa +  IL-2  65  11  22  7 
(Thy-l.l ----}  Thy-l.2)§ 
40:1  4:1  40:1  4:1 
Control chimera H  (Thy-l.2 ~  Thy-l.1)  (B6 ×  DBA/2)FI +  IL-2  70  48  27  14 
Thymectomized chimera  (B6 X DBA/2)FI +  IL-2  88  54  35  9 
(Thy-1.2 ~  Thy-1. t)l  I 
Thymectomized chimera  (B6 ×  DBA/2)F1 +  IL-2  68  32  13  9 
(Thy-1.2 --* I. l)ll 
* 5 ×  106 s~leen cells were cultured for 5 d with 5 ×  l06 stimulator cells with 5% IL-2. 
Specific SICr release at the indicated effector-to-target ratios.  Spontaneous release for P815 was  14-27% 
and  11-15% for EL4-TNP. 
§Chimeras  Thy-l.l  ~  Thy-l.2  (cf legend  Table  I).  Data  from  two control  and  three  thymectomized 
chimeras. 
I[ Chimeras Thy-l.2 --', Thy-l.1. Data from one control and two thymectomized chimeras. 
demonstrated that the spleen cells of thymectomized chimeras had the same amount 
of Thy-1  on  their  surface  as  the  thymocytes  from  normal  Thy-1  mice  (i.e.,  high 
Thy-1), whereas the spleen cells from nonthymectomized mice had the same amount 
of Thy-1 as spleen from normal B6 Thy-1  mice  (i.e., low Thy-1)  (data not shown). 
It  has  been  demonstrated  (27)  that  early  in  ontogeny,  allogeneic  pre-CTL  are 
Ly-1+2 +, whereas later in development  their phenotype is Ly-l±2 +, i.e., they express 
low amounts of the Ly-1  antigen. Therefore,  if allogeneic pre-CTL  from  thymecto- 
mized  chimeras  expressed  a  more  immature  phenotype than normal  pre-CTL,  one 
might expect this to be reflected  in their Lyt phenotype. Table XI demonstrates that 
allogeneic pre-CTL from thymectomized chimeras were very susceptible to treatment 
with  monoclonal anti-Ly-l.2  plus C,  i.e.,  they express  the more  immature  Ly-l+2 + 
phenotype,  whereas  those  from  normal  spleen  and  control  chimeras  are  far  less 
susceptible,  i.e., Ly-1 ±. All pre-CTL were eliminated  by treatment with monoclonal 
anti-Ly-2.2  plus  C  (data  not  shown).  All  TNP-specific  pre-CTL  were  Ly-l+2 +,  as 
previously described  (27, 28). 
Discussion 
An attempt has been made to develop a model system to study extrathymic T  cell 
differentiation. Given the concerns surrounding the use of nude mice, we decided  to 
use  thymectomized,  lethally  irradiated,  and  bone  marrow-reconstituted  mice  to VERONIQUE  DUPREZ,  BRIAN HAMILTON,  AND STEVEN J.  BURAKOFF 
TABLE IX 
Cross-reactivity of Alloreactive CTL on a Third-Party  Allogeneic Target 
853 
Experi- 
ment  Responder  Stimulator 
Target 
RDM4  DBA/1 blasts 
50:1  10:l  2:1  50:1  10:1  2:1 
Normal B6 Thy-l.2  (B6 × C3H)FI  40  28  6*  NT~ 
Normal B6 Thy-l.2  (B6 × C3H)Fa + IL-2  60  35  9  36  7  2 
Control chimera  (B6 × C3H)F1  37  18  7  NT 
(Thy-  1.2 ~  Thy-l.1)§ 
Control chimera  (B6 × C3H)F1 + IL-2  47  30  5  30  6  0 
(Thy-  1.2 ---* Thy- 1.1)§ 
Thymectomized chimera  (B6 × C3H)F1  11  5  2  NT 
(Thy-l.2 --* Thy-l.1)§ 
Thymectomized chimera  (B6 x C3H)Fx + IL-2  72  68  54  43  27 
(Thy-  1.2 --~ Thy-l.l) 
P815  RDM4 
50:1  5:1  50:l  5:1 
Normal B6 Thy-1.2  BALB/c + IL-2  60  48  41  29 
Control chimera  BALB/c + IL-2  56  25  41  22 
(Thy-l.2 ~  Thy- 1.2)11 
Thymectomized chimera  BALB/c  + IL-2  59  50  66  33 
(Thy-l.2 ---* Thy-l.2)l  { 
12 
* Specific 51Cr release at the indicated effector-to-target ratios. Spontaneous release for RDM4 was  12% 
and 35% for DBA/1 LPS blasts (experiment 1), 10% for P815, and 33% for RDM4 (experiment 2). 
:~ Not tested. 
§ Chimera Thy- 1.2 ~  Thy-l.l. 
II Chimera Thy-l.2 ~  Thy-l.2. 
address this issue. Though previous studies had proposed that spleen cells from such 
mice lacked functional T  cells, based on the experience with nude mice, we proposed 
that IL-2 might provide the additional signal needed to drive pre-CTL to functional 
T  cells. The results reported here are consistent with this proposal. We found that the 
spleens of these  mice  contain Thy-l-positive cells  capable  of becoming functional 
CTL  recognizing alloantigens or TNP-modified syngeneic antigens when cultured 
with antigen and IL-2. By using Thy-1 congenic mice, we have been able to avoid 
allogeneic differences that might result in allogeneic effects but still have a  marker to 
demonstrate the donor origin of the CTL generated. 
There are several issues relating to extra-thymic differentiation that we have begun 
to address, namely, the stage of differentiation of these splenic pre-CTL and the CTL 
repertoire found in these thymectomized mice. By using Thy- 1.1 donor cells, we have 
been able to easily use susceptibility to lysis by anti-Thy-1.1 plus C  as a parameter to 
determine  the  state  of  maturation  of  the  pre-CTL.  It  has  been  observed  that 
thymocytes are high in Thy-1.1 expression but that peripheralized T  cells, including 
pre-CTL, express  little Thy-l.1  and, in fact,  are  difficult to  lyse with  anti-Thy-l.1 854  GENERATION OF CYTOLYTIC T  LYMPHOCYTES 
TABLE  X 
Sensitivity to Anti-Thy-1.1  and C Treatment of CTL Precursors  from Thymectomized  Chimeras 
Percent specific 
51Cr release of 
Experi-  Responder*  Treatment  Stimulator  EL4-TNP:~ 
ment 
50:1§  10:1  2:1 
Control chimerall  None  B6-TNP  41  21 
Control chimerall  None  B6-TNP +  IL-2  61  39 
Control chimerall  Anti-Thy-1.1  +  C¶  B6-TNP +  IL-2  57  35 
Thymectomized chimera  None  B6-TNP  0  0 
Thymectomized chimera  None  B6-TNP +  IL-2  52  32 
Thymectomized chimera  Anti-Thy-l.l + C  B6-TNP +  IL-2  13  0 
Control chimera  None  B6-TNP  84  79  43 
Control chimera  None  B6-TNP +  IL-2  83  72  34 
Control chimera  Anti-Thy-l.1 +  C  B6-TNP +  IL-2  83  84  44 
Thymectomized chimera  None  B6-TNP  4  5  0 
Thymectomized chimera  None  B6-TNP +  IL-2  76  61  16 
Thymectomized chimera  Anti-Thy-l.1 + C  B6-TNP +  IL-2  18  l0  2 
Normal B6 Thy- 1.1  None  B6-TNP  86  85  60 
Normal B6 Thy-1.1  None  B6-TNP +  IL-2  82  87  56 
Normal B6 Thy- 1.1  Anti-Thy- 1.1 +  C  B6-TNP +  IL-2  80  78  39 
* 5 ×  10  6 spleen cells were cultured for 5 d with 5 ×  l0  s stimulator cells with or without 5% IL-2. 
:~ Spontaneous release of EL4-TNP ranged from 7-17%. 
§ Effector-to-target  ratio. 
IIChimeras Thy- 1.1 --~ Thy- 1.2 (cf legend Table I). 
¶ 5 ×  l0  s spleen cells were treated twice with anti-Thy-l, l at a  l0  -a dilution and complement at a dilution 
of 10  -I • 
plus C. Once stimulated with antigen to become functional CTL,  these cells again are 
high in Thy-1.1  expression and  are readily susceptible  to lysis by anti-Thy-1.1  plus C 
(22).  The  splenic  pre-CTL  from  thymectomized  mice  were  found  to  be  high  in 
Thy-l.1,  which  could  place  their  stage  of differentiation  at  that  of thymocytes  or 
mature T  cells. Because thymocytes require exogenous IL-2 to respond  to antigen  (29, 
30)  and  mature  splenic T  cells do  not,  it would appear  that  the splenic  pre-CTL  of 
thymectomized  mice  are  at  a  stage  of differentiation  similar  to  that  of thymocytes. 
The  more immature  Lyt phenotype  of the allogeneic pre-CTL  from these thymecto- 
mized chimeras is also consistent with this proposal. This suggests that in mice lacking 
a  thymus,  T  cell differentiation  occurs  in  the spleen  and  never reaches  the  stage  of 
differentiation  of normal  splenic  T  cells;  however,  addition  of exogenous  IL-2  and 
antigen  in  vitro will allow them  to  differentiate  to  mature  CTL.  To be certain  that 
our bone marrow  inoculum did not contain a  pre-CTL  that  required exogenous IL-2 
to respond  to antigen,  we determined  that,  after our anti-Thy-1.1  plus C  treatment, 
there were no pre-CTL  capable of responding  to antigen,  even when IL-2 was added 
(Tables V  and  VI). This would strongly suggest  that  differentiation  to a  Thy-1 + pre- 
CTL  requiring exogenous IL-2 had  occurred  in these thymectomized  mice. 
In our initial  analysis  of the CTL  repertoire of these  mice, there  are a  number  of 
similarities and  several  discrepancies  when  compared  with  the observations  made  in VERONIQUE  DUPREZ,  BRIAN  HAMILTON, AND STEVEN  J.  BURAKOFF 
TABLE XI 
Sensitivity of CTL Precursors  from  Thymectomized Chimeras to Anti-Ly-l. 2 plus C 
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Responder*  Stimulator  Target 
Treatment 
Anti-  None  Ly-l.2 + C 
30:1  6:1:~ 30:1  6:1 
Control chimera§  B6-TNP + IL-2  EL4-TNP  42  211[  0  0 
Thymectomized chimera  B6-TNP + IL-2  EL4-TNP  45  24  8  3 
Normal B6 Thy-l.1  B6-TNP + IL-2  EL4-TNP  52  19  5  0 
Control chimera  (B6 × DBA/2)F1 + IL-2  P815  78  78  55  29 
Thymectomized chimera  (B6 × DBA/2)F1 + IL-2  P815  85  82  5  0 
Normal B6 Thy-l.1  (B6 × DBA/2)F~ + IL-2  P815  89  87  96  63 
* Responder cells are 5 ×  l0  6 spleen cells cultured with 5 ×  10  6 stimulator cells and 5% IL-2. Chimeras are 
Thy-l.1 ~  Thy-l.2 (cf legend Table I). 
:~ Effect  or-t arget-rat io. 
§ 25 ×  106 spleen cells were treated twice with a monoclonal anti-Ly-l.2 antibody at a dilution of 4 ×  10  -4 
and complement at 10  -1  . 
II Percent specific 51Cr release. Spontaneous release was 5-7% for EL4-TNP and 13% for P815. 
nude mice.  (a)  We found the CTL  generated to TNP-modified syngeneic cells to be 
H-2  restricted.  The  degree of cross-reactivity to TNP-modified  allogeneic cells was 
similar to that reported for normal B6 mice (20). There is, however, conflicting data 
concerning the  H-2  restriction of nude  mice.  Gillis and  Watson  (31)  have  reported 
that  the CTL  generated  in  nude  mice to TNP-modified  syngeneic cells were  unre- 
stricted.  Several  groups,  however,  have  reported  H-2-restricted CTL  generated  in 
nude mice, including CTL generated to TNP-modified syngeneic cells (10,  11, 32). 
(b)  Hunig and  Bevan  (10)  have observed that  CTL  generated  from  nude  mouse 
spleen cells to  allogeneic cells do not  demonstrate  cross-reactive lysis of third-party 
allogeneic target cells. Their data would suggest that  the thymus may influence the 
ultimate CTL  repertoire. Our thymectomized mice did demonstrate cross-reactivity 
and, thus,  our findings are at odds with those of Hunig and Bevan.  Admittedly, we 
examined different strain combinations, and it is possible that their strain combina- 
tions  fortuitously uncovered  a  "hole"  in  the CTL  repertoire that  we  missed. These 
differences, however, may reveal a  difference, on a clonal level, in the T  cell repertoire 
of  nude  mice  compared  with  thymectomized  mice.  As  we  proceed  with  a  more 
detailed analysis of the CTL repertoire in these mice, we might yet uncover defects or 
holes in their repertoire that reflect a  thymic influence on the CTL repertoire. 
(c) A  third aspect of the CTL  repertoire has also been studied and is also at odds 
with the observations of Hunig and Bevan  (21).  Hunig and Bevan found that when 
(A  ×  B)F1  mice  were  given  an  A  thymus,  CTL  generated  from  these  mice  to 
alloantigen C  would cross-react on A-TNP but  not on  B-TNP.  They suggested that 
this demonstrated the influence of the thymus on the CTL  repertoire, i.e., the cross- 
reactivity  of alloreactive  CTL  for  TNP-modified  syngeneic  cells,  which  has  been 
observed in normal  mice  (17).  Our thymectomized mice, however, did demonstrate 856  GENERATION OF CYTOLYTIC T  LYMPHOCYTES 
this cross-reactivity. It has been argued that  the reason  (A ×  B)F1  mice given an A 
thymus respond only to A  +  X  but not B +  X  is due to suppressor cells that inhibit 
the response to B  +  X. Admittedly,  these suppressors have not  been demonstrated, 
but,  if such cells exist, they should  also suppress the clones of CTL that were cross- 
reactive for B-TNP, even if generated by stimulation with antigen C. 
We  were  obviously concerned  by  our  inability  to  find  any  holes  in  the  T  cell 
repertoire.  Because  B6  Thy-l.1  T  cells  express  low  amounts  of Thy-1  antigen  at 
certain stages of differentiation, we were concerned that some T  cells recirculating to 
the bone marrow could  escape anti-Thy-l.1  plus  C  treatment  and  account  for the 
pre-CTL found in the spleens of the thymectomized chimeras. This, however, seems 
unlikely for several reasons.  (a)  The pre-CTL we detect  in  the spleens of thymecto- 
mized chimeras express high amounts ofThy-1.1 antigen, and, if such cells recirculated 
to  the  bone  marrow,  they  should  be  eliminated  easily  with  anti-Thy-l.1  plus  C 
treatment.  (b) We demonstrated that there were no detectable pre-CTL in the bone 
marrow inoculum after double anti-Thy-1 plus C  treatment, for no cytolytic activity 
could be generated even when IL-2 was added with antigen (Tables V  and VI). These 
treated  bone marrow cells also failed  to proliferate to the mitogen concanavalin A 
(data not shown). (c) Pre-CTL from B6 Thy- 1.2 --~ B6 Thy- 1.1 chimeras demonstrated 
the same requirement  for IL-2, and  cross-reactive CTL was  found  both  for the  B6 
Thy-l.1 ~  B6 Thy-l.2 and B6 Thy-l.2 ~  B6 Thy-l.1  chimeras (Tables I, IV, VII, 
VIII, and  IX).  B6 Thy-l.2 T  cells remain susceptible to treatment  by anti-Thy-l.2 
plus C  at  all stages of their differentiation:  bone marrow cells,  thymocytes, splenic 
pre-CTL, and CTL from B6 Thy-l.2 mice and B6 Thy-l.2 --) B6 Thy-l.1  chimeras 
(control  and  thymectomized)  were  susceptible  to  anti-Thy-l.2  plus  C  treatment. 
Therefore,  anti-Thy-l.2  plus  C  treatment  of  bone  marrow  should  eliminate  all 
Thy-l.2 T  cells.  (d)  To be certain  that  we had not left a  thymic remnant, we have 
done  appropriate serial sections  on  thymectomized chimeras and  found  no  thymic 
tissue  by histological  analysis.  (e)  The pre-CTL from our chimeras express the  Lyt 
antigens,  making it  unlikely  that  the cytolytic activity we observed is  the  result  of 
natural killer cell activity (Table XI). 
Stutman  (33)  has  proposed  that  a  Thy-l-negative  T  cell  that  has  undergone 
processing in  the  thymus  may exist.  Though  such  a  cell  has  not  been  definitively 
identified, such a  cell could account for the discrepancies found between nude mice 
and our thymectomized mice.  One could speculate that  the reason we cannot  find 
holes  in  the  repertoire  is  that  these  Thy-l-negative cells  are  in  the  bone  marrow 
inoculum  given  to  the  thymectomized,  irradiated  mice,  and  in  the  recipient  they 
differentiate  to  express  the  Thy-1  marker.  Experiments  using  fetal  liver  or  bone 
marrow from nude mice are in progress to test this hypothesis. Preliminary data with 
fetal  liver  reconstituted  chimeras  suggest  that  they  give  similar  results  (data  not 
shown). 
The model system we presented here can be used to study extrathymic differentia- 
tion but it may also provide insights into the problems one might encounter in the 
bone marrow transplantation of patients with thymic dysfunction. For example, older 
transplant patients might have involuted thymuses and their thymic function might 
be  compromised.  It  is  important  to  determine  whether  there  will  only  be  partial 
immune reconstitution of these patients, i.e., they will have holes in their repertoire. 
If defects in their T  cell repertoire occur, especially for the recognition of viruses, these VERONIQUE DUPREZ,  BRIAN HAMILTON, AND  STEVEN J.  BURAKOFF  857 
patients may be at greater risk for viral infections or malignancies.  If such defects are 
identified,  perhaps  the  full  reconstitution  of their  immune  system  may require  the 
addition of various interleukins  together with bone marrow transplantation. 
Summary 
A  model  system has  been  developed  to study  extrathymic  T  cell  differentiation. 
Mice  have  been  thymectomized,  lethally  irradiated,  and  reconstituted  with  bone 
marrow  cells  depleted  of Thy-1-positive  cells.  After 8  wk,  the  spleen  cells  of these 
5athymic, bone marrow-reconstituted  chimeras  contain Thy-l-positive  pre-cytolytic 
T  lymphocytes  (CTL)  that  are  able  to  respond  to  antigen  only  when  exogenous 
interleukin  2 is added to culture.  The phenotype of these pre-CTL is similar to that 
of thymocytes, suggesting that they may be an immature T  cell. Initial evaluation of 
the CTL repertoire  of these athymic mice demonstrates  that  the CTL generated  to 
trinitrophenyl-modified syngeneic cells are H-2 restricted and that the CTL generated 
to alloantigens have many of the cross-reactivities observed in normal but not in nude 
mice. The discrepancies observed in the CTL repertoire between these thymectomized 
chimeras and nude mice are discussed. 
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